Literature DB >> 14522931

Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest.

Kathy Kamath1, Mary Ann Jordan.   

Abstract

The epothilones are a group of novel microtubule-targeted, antimitotic compounds that have a paclitaxel-like, assembly enhancing effect on tubulin in vitro as well as in cultured cells. We hypothesize that epothilones induce mitotic arrest by suppressing microtubule dynamics. To test this hypothesis, we used MCF7 cells stably transfected with GFP-alpha-tubulin to analyze microtubule dynamics at three concentrations of epothilone B, one that induced no mitotic arrest (0.2 nM, 20 h), one that induced one-third maximal mitotic arrest (IC(33,) 2 nM, 20 h), and one that induced half-maximal mitotic arrest (IC(50,) 3.5 nM, 20 h). We found that epothilone B suppressed microtubule dynamics in a concentration-dependent manner coincident with mitotic block. At 0.2 nM epothilone B, dynamics were not significantly altered. At 2 nM epothilone B (IC(33)), the mean growth and shortening rates were decreased by 38 and 27%, respectively. Dynamicity was decreased by 47%. At the IC(50), 80% of the cells had nearly complete stabilization of microtubule dynamics, and no anaphase or telophase figures were observed. Comparison of the effects of epothilone B on microtubule dynamics with those of paclitaxel indicated that both drugs alter the same microtubule dynamic parameters to a similar extent. At the IC(50) for mitotic arrest, dynamicity was reduced by 54% by paclitaxel compared with 62% for epothilone B. In 65% of the cells treated with paclitaxel, the microtubules were completely stabilized. Thus, the effects of epothilone B on microtubule dynamics are remarkably similar to those of paclitaxel, suggesting that both drugs induce mitotic block by a similar mechanism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14522931

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

1.  Synthesis and biological evaluation of 2-amino-1-thiazolyl imidazoles as orally active anticancer agents.

Authors:  Wen-Tai Li; Der-Ren Hwang; Jen-Shin Song; Ching-Ping Chen; Tung-Wei Chen; Chi-Hung Lin; Jiunn-Jye Chuu; Tzu-Wen Lien; Tsu-An Hsu; Chen-Lung Huang; Huan-Yi Tseng; Chu-Chung Lin; Heng-Liang Lin; Chung-Ming Chang; Yu-Sheng Chao; Chiung-Tong Chen
Journal:  Invest New Drugs       Date:  2010-10-02       Impact factor: 3.850

2.  Metronomic dosing enhances the anti-angiogenic effect of epothilone B.

Authors:  Mark W Stalder; Catherine T Anthony; Eugene A Woltering
Journal:  J Surg Res       Date:  2009-12-30       Impact factor: 2.192

3.  The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner.

Authors:  Jun Zhou; Chantal Chanel Vos; Ada Gjyrezi; Minoru Yoshida; Fadlo R Khuri; Fuyuhiko Tamanoi; Paraskevi Giannakakou
Journal:  J Biol Chem       Date:  2009-02-18       Impact factor: 5.157

4.  Tropomyosin isoform expression regulates the transition of adhesions to determine cell speed and direction.

Authors:  Cuc T T Bach; Sarah Creed; Jessie Zhong; Maha Mahmassani; Galina Schevzov; Justine Stehn; Lauren N Cowell; Perttu Naumanen; Pekka Lappalainen; Peter W Gunning; Geraldine M O'Neill
Journal:  Mol Cell Biol       Date:  2009-01-05       Impact factor: 4.272

5.  Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy.

Authors:  Nichole E LaPointe; Gerardo Morfini; Scott T Brady; Stuart C Feinstein; Leslie Wilson; Mary Ann Jordan
Journal:  Neurotoxicology       Date:  2013-05-24       Impact factor: 4.294

6.  Suppression of microtubule dynamic instability and turnover in MCF7 breast cancer cells by sulforaphane.

Authors:  Olga Azarenko; Tatiana Okouneva; Keith W Singletary; Mary Ann Jordan; Leslie Wilson
Journal:  Carcinogenesis       Date:  2008-10-23       Impact factor: 4.944

7.  Tubulin binding cofactor C (TBCC) suppresses tumor growth and enhances chemosensitivity in human breast cancer cells.

Authors:  Rouba Hage-Sleiman; Stéphanie Herveau; Eva-Laure Matera; Jean-Fabien Laurier; Charles Dumontet
Journal:  BMC Cancer       Date:  2010-04-12       Impact factor: 4.430

Review 8.  Microtubule-stabilizing drugs from marine sponges: focus on peloruside A and zampanolide.

Authors:  John H Miller; A Jonathan Singh; Peter T Northcote
Journal:  Mar Drugs       Date:  2010-03-31       Impact factor: 5.118

Review 9.  Present and future evolution of advanced breast cancer therapy.

Authors:  Ricardo H Alvarez
Journal:  Breast Cancer Res       Date:  2010-10-22       Impact factor: 6.466

10.  Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer.

Authors:  David W Miles
Journal:  Breast Cancer Res       Date:  2009-08-28       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.